BLGO — BioLargo Cashflow Statement
0.000.00%
Last trade - 00:00- $54.20m
- $50.24m
- $7.77m
Annual cashflow statement for BioLargo, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.89 | -5.13 | -4.65 | -4.35 | -15.2 |
| Depreciation | |||||
| Non-Cash Items | 2.69 | 2.58 | 3.26 | 2.61 | 7.77 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.249 | -0.25 | -1.08 | -1.62 | -1.14 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -3.94 | -2.76 | -2.37 | -3.21 | -8.3 |
| Capital Expenditures | -0.034 | -0.271 | -0.478 | -1.24 | -0.046 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | — | — | -0.082 | 0.481 |
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.034 | -0.271 | -0.478 | -1.32 | 0.435 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.23 | 3.96 | 4.66 | 4.44 | 8.22 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.246 | 0.889 | 1.69 | 0.009 | 0.335 |